Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
Introduction
Germ-cell tumors (GCTs) are the most common cancer in men between 15 and 35 years of age, with an estimated 8720 cases diagnosed annually in the United States and 410 deaths [1] . First-line chemotherapy with bleomycin-etoposide-cisplatin (BEP) became the standard of care for patients with advanced GCT [2] [3] [4] [5] . The International Germ Cell Cancer Collaborative Group (IGCCCG) in 1997 published a consensus statement classifying patients with metastatic GCT into good, intermediate, and poor risk disease [6] . Good risk GCT had a 5-year progression-free survival (PFS) of 88% and a 5-year overall survival (OS) of 91%. Intermediate risk GCT had a 5-year PFS of 75% and a 5-year OS of 79%. The poor risk category had a 5-year PFS of 41% and a 5-year OS of 48%.
The optimal management of GCTs is complex, with options including chemotherapy and surgery. At Indiana University Cancer Center (IU), we have established a multidisciplinary clinic (MDC) to evaluate newly diagnosed GCT patients and those needing additional consultation. The goals of this MDC are to provide state-of-the-art oncology care and to educate patients, their families, medical students, residents, and fellows in training. Our MDC integrate dedicated team including medical oncologists, pathologists, urologic and thoracic surgical oncologists, full-time coordinator (responsible for data acquisition, scheduling, and following up with patients and referring physicians) and oncology nurses. The team meets on a weekly basis in a multidisciplinary tumor board. Through this clinic, we can establish the accurate pathologic diagnosis, offer combination chemotherapy, surgical resection of residual tumor and enroll patients on clinical trials all in one visit (supplementary Figure S2 , available at Annals of Oncology online).
Institutional experience, hospital and physician volume have been associated with improved outcomes of testicular cancer [7] [8] [9] [10] . Recent outcome data from large datasets are missing, and the difference in results of patients treated in large volume centers and community centers is unknown. We, therefore, report survival outcomes in 704 consecutive patients with metastatic GCT treated at our MDC at IU since the publication of IGCCCG and compare the outcome to those of National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
Patients and methods

Patients
The IU Cancer Registry database was queried, and a retrospective review was carried out to compare the PFS and OS of patients treated at IU with that of IGCCCG [6] . This study used the secure Web-based, Title 21 Code of Federal Regulations Part 11-compliant Research Electronic Data Capture (REDCap) system for data input. Eligible patients who had metastatic GCT treated at IU after the establishment of IGCCCG between January 1998 and December 2014 were included. All patients were treated with standard cisplatin-etoposide-based combination chemotherapy consisting of at least three to four cycles of cisplatin and etoposide with or without bleomycin or ifosfamide [11, 12] . SEER Research Data (1973 was also obtained to compare OS of the IU cohort the SEER distant cohort. The SEER distant cohort consisted of patients in the SEER database with testis cancer diagnosed between 2000 and 2014, who had an SEER historical stage of distant, and who had available survival data [13] .
Statistical analysis
The end points of the study were the PFS and OS probabilities at 5 years. For the IU cohort, PFS started with the initiation of chemotherapy and ended with progression or death, whichever occurred first. OS started with the initiation of chemotherapy and ended with the death of a patient. Survival status was identified from medical charts or death certificates. Patients without an event were censored at the date of last followup. For the SEER distant cohort, OS started with the date of diagnosis and ended with the death of a patient. Patients alive at the date of last contact were censored. PFS and OS were calculated according to the Kaplan-Meier method and using the log-rank test. Analyses were completed compared using SAS software, version 9.4 and figures were created in R, version 3.3.2. Five-year PFS and OS were reported along with 95% confidence intervals (CIs) calculated using the log-log method.
Results
Patient and disease characteristics
For the IU cohort, 1611 consecutive patients with metastatic GCT were evaluated in the MDC at IU between 1998 and 2014. Of these, 704 patients started the initial chemotherapy at IU and were included in the primary outcome analysis (supplementary Figure S1 , available at Annals of Oncology online). Median age at diagnosis was 29 (range 13-62). Median follow-up time was 4.4 years. The primary tumor site was testis in 622 (88.4%), retroperitoneum in 26 (3.7%), and mediastinum in 54 (7.7%). Eightyfive percent of patients had nonseminomatous GCT (NSGCT). Ninety-seven percent of patients were white, 1% were black, and the remaining 2% were a variety of races/ethnicities. Of note, we did not include LDH in our database. Elevations in LDH are highly nonspecific and may be found in a vast number of benign and malignant conditions [14] . Table 1 lists patients and disease characteristics at the time of initiation of first-line chemotherapy. Supplementary Figure S3 , available at Annals of Oncology online, presents a map of the United States showing the zip codes of patients seen at our center.
For the SEER distant cohort, 1283 patients were identified from the SEER database with testis cancer diagnosed between 2000 and 2014. To be included in the cohort, patients must have had an SEER historical stage of distant and available survival data. Patients with a survival time of 0 (i.e. date of diagnosis and date of last contact are the same) were excluded. Median age at diagnosis was 32 (range 0-87). Eighty-seven percent of patients were white, 5% were black, and the remaining 8% were a variety of races/ethnicities. A 73.5% of patients had NSGCT.
Treatment administration
All 704 assessable patients in the IU cohort were treated with cisplatin-etoposide combination chemotherapy. Details regarding first-line treatment regimen stratified per IGCCCG risk classification are listed in Table 1 . Overall, 82% of patients achieved a complete response and remained disease-free after first-line chemotherapy. A total of 250 patients (36%) underwent post-chemotherapy retroperitoneal lymph node dissection (PCRPLND), 129 (18%) thoracic surgery, 21 cervical lymph node dissection and 9 patients had a resection of brain metastasis. One hundred and fifty-three patients failed first-line chemotherapy, 118 received salvage chemotherapy including high-dose chemotherapy (HDCT) (n ¼ 76), and 51 had salvage surgery. At last follow-up, 635 patients (90%) had no evidence of disease (NED), 65 patients (9%) had died, and 4 patients (1%) were alive with relapsed disease. Among patients who died, 52 patients were dead of disease progression, and 13 patients died of other causes including treatment-related toxicity, secondary malignancy, or surgical complications.
We also reviewed the GCT patients who came to IU for a second opinion. Nine hundred and seven patients sought a second opinion or were evaluated after receiving first-line therapy at an outside institution and were not included in the primary analysis.
Four hundred and ninety-two (56%) underwent PCRPLND, 432 (51%) underwent salvage chemotherapy, and 172 (21%) underwent thoracic surgery as a result of the multidisciplinary evaluation.
Survival outcomes
With a median follow-up of 4.4 years, the estimated 5-year PFS was 79% (95% CI 76% to 82%) and the 5-year OS was 90% (95% CI 87% to 92%) for the IU cohort ( Table 2 ). The 5-year PFS for good, Intermediate and poor risk were 90%, 84%, and 54%, respectively ( Figure 1A) , and the estimated 5-year OS was 97%, 92%, and 73% ( Figure 1B) , respectively. In sub-segment of patients with testis as the primary site at presentation (IU testis cohort n ¼ 622), the 5-year OS was 94% (95% CI 91% to 96%). Patients with primary mediastinal nonseminomatous GCT (PMNSGCT) had an estimated 5-year PFS of 50% (95% CI 35% to 63%) and 5-year OS of 59% (95% CI 43% to 72%). Patients with brain metastasis at diagnosis had an estimated 5-year PFS of 15% (95% CI 5% to 28%) and 5-year OS of 46% (95% CI 28% to 63%).
To demonstrate the impact of our MDC approach, we compared OS of patients in the IU testicular primary cohort with the SEER distant cohort. The 5-year OS for the SEER distant cohort was 75% (95% CI 73% to 78%) compared with 94% (95% CI 91% to 96%) for IU testis cohort (P-value <0.0001; Figure 2 ). The SEER database does not allow stratification according to the IGCCCG risk category; therefore comparisons of survival between groups are not possible.
Discussion
To our knowledge, this is the largest single-institution study evaluating survival outcomes of patients with metastatic GCT. Survival results of patients treated at IU appear superior to the results of the IGCCCG (Table 2 ) and the NCI SEER distant cohort (Figure 2) . This observation is supported by a large multiinstitutional initiative that provided outcome results from highvolume centers that were superior to the original IGCCCG [15] . These data were, however, not directly compared with community outcomes. Several factors may account for excellent survival outcomes seen at our center compared with the IGCCCG and SEER database. This could be attributed to the uniform utilization of cisplatin-etoposide-based combination chemotherapy, improvement in supportive care avoiding delays between cycles, expertise in post-chemotherapy surgical resection of residual disease and the experience resulting from a large volume of patients. Our dedicated multidisciplinary team of medical, urologic and thoracic oncologists, and pathologists have specific academic interest in GCT supported by strong research and clinical trials designed to refine treatment, improve supportive care, and patient education.
Surgical treatment is crucial for the management of metastatic GCT to improve survival and reduce complications [16, 17] . Appropriate patient selection and timing of surgery have lowered morbidity while improving oncologic outcomes at high volume centers [18, 19] . The marked improvement in OS in all-risk categories maybe driven by the development of successful salvage therapy options including salvage surgery, and the long-term experience in HDCT followed by autologous peripheral blood stem-cell transplant [20] [21] [22] [23] [24] [25] .
This analysis has limitations. This is a retrospective single institution study, and potential bias exists in our patient population. We did not have access to matched patient's characteristics between the contemporary IU cohort and the historical IGCCCG cohort, and the community patients reported in SEER. Referral bias might have affected the results of this study. However, this study has a large sample size of consecutive patients with metastatic GCT treated at a tertiary care center with long follow-up. A large portion of patients enrolled in the study had poor risk disease 25.7% compared with 14% of patients from the IGCCCG [6] ; hence survival outcomes for patients treated at other institutions or in the community might vary. Besides, a limitation of this study is that NCI SEER uses a staging system including local, regional, and distant metastases which are not typically used in GCT. The IGCCCG classification of good, intermediate, and poor risk is not included in the SEER database which makes further analysis not possible. That is why we compared all patients with metastatic disease as one group.
Despite substantial improvement in outcomes of patients with metastatic GCT treated in the modern era, many challenges remain. There is a clear disparity in health care outcomes among patients with testis cancer [26] [27] [28] . This could be related to patient's factors such as under insurance, poor socioeconomic status, ethnicity, and a language barrier that delays diagnosis. Also, it could be attributed to the rare nature of this cancer and lack of experience in the community to establish an accurate diagnosis and deliver a treatment plan.
In conclusion, in this modern cohort of newly diagnosed metastatic GCT, there was an improvement in PFS and OS for good, intermediate, and poor-risk disease compared with IGCCCG. Furthermore, we demonstrated that a multidisciplinary team care approach is associated with improved survival outcomes compared with SEER distant cohort. Taken together, these data support reconstructing health delivery models to enhance value and improve clinical outcomes [9, 19] .
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